熱門資訊> 正文

Palvella Therapeutics推出1.5亿美元公开募股

2026-02-25 05:21

Palvella Therapeutics (PVLA) announced the commencement of an underwritten public offering of $150M of its common stock.
The company expects to grant underwriters a 30-day option to purchase up to an additional $22.5M of shares.
All shares in the proposed offering will be sold by Palvella.
Net proceeds are intended to advance development of QTORIN rapamycin and QTORIN pitavastatin programs, as well as for working capital, research and development, and general corporate purposes.

More on Palvella Therapeutics

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst
Palvella surges on late-stage trial win for lead asset
Adagene, Palvella gain after FDA Fast Track Designations
Seeking Alpha’s Quant Rating on Palvella Therapeutics
Historical earnings data for Palvella Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。